SEARCH

SEARCH BY CITATION

Keywords:

  • breast cancer;
  • upper-body morbidity;
  • lymphedema;
  • incidence;
  • prevention;
  • treatment

Abstract

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions. Cancer 2012;118(8 suppl). © 2012 American Cancer Society.


Overview of the Epidemiology of Upper-Body Morbidity

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Upper-body morbidity after breast cancer is typically characterized by the presence of sensory or motor symptoms and impairments such as pain, weakness, tightness, poor range of motion, nerve palsies, altered movement patterns or muscle recruitment, numbness, or swelling in the shoulder, arm, and/or breast of the affected side. Upper-body morbidity is typically associated with alterations in the use and function of the upper body and adverse physical, psychosocial, and social ramifications that profoundly influence all aspects of daily life and hence quality of life (QOL).1-7 Arguably, lymphedema (swelling) is regarded as the most feared and problematic.5 The purpose of this paper is to review upper-body morbidity incidence and risk factors, methods for diagnosis, and prevention and treatment strategies. The evidence base for integration of prospective surveillance of upper-body morbidity within standard clinical care of women with breast cancer will also be highlighted.

Incidence of Upper-Body Morbidity After Breast Cancer

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Upper-body symptoms and impairments

Despite advances in breast cancer treatment methods that have led to less invasive surgical techniques, such as sentinel node biopsy,8, 9 and more refined radiation techniques, such as intensity modulation,10, 11 upper-body symptoms and impairments that impact function and QOL remain common. Incidence of individual symptoms, such as pain and weakness, as well as nerve palsies, skin fragility, soft tissue fibrosis, and inflammation have been the focus of prior research studies.12-21

In the past 10 years, the presence of upper-body symptoms after breast cancer has been evaluated in >20 studies,2, 9, 22-41 including 7 cohort studies involving population-based samples (Table 1).22-24, 27, 33, 34, 42 A wide range in prevalence was reported across these studies, with higher rates generally observed in cohort studies compared with clinical trials. Symptoms (which may have included any 1 or more of the following: weakness, stiffness, numbness, tingling, pain, poor range of motion, swelling) were assessed in these studies via self-report methods using validated or nonvalidated questions. The majority of studies assessed only a subset of the known symptoms reported by women with breast cancer (eg, weakness, stiffness, and tingling were rarely assessed), and it is plausible that the entire spectrum of possible upper-body symptoms that women may experience is yet to be fully understood. The inclusion of mild symptoms as being indicative of morbidity was variable. At least 10%, but as many as 60%, of women report at least 1 upper-body symptom at any point from 6 months to 3 years after breast cancer surgery (Table 1). Pain (eg, breast, axilla, myofascial pain) has possibly received the most attention of all symptoms, with its prevalence ranging from 12% to 51%.13, 14

Table 1. Prevalence of Upper-Body Symptoms Reported by Prospective, Population-Based Cohort Studies
StudySample size, N (Country)Symptoms AssessedMonths After Breast Cancer Diagnosis/Surgery (Any one symptom prevalencea)
6 (10%-53%)12 (10%-61%)18 (10%-44%)24 (21%-66%)36 (19%-54%)
  • Abbreviation: ROM, range of movement.

  • a

    Studies measured at least one of the following symptoms: tingling, weakness, pain, poor range of movement (ROM), numbness, stiffness, swelling; may have included mild symptoms and used various self-report methods including items from quality of life questionnaires or unvalidated items.

1. Albert 200622389 (Germany)Swelling, poor ROM, pain27%19%20%21%19%
2. Arndt 200623314 (Germany)Swelling, poor ROM, pain 24%-30%   
3. Engel 200324990 (Germany)Swelling, poor ROM 47% 44%40%
4. McCredie 200133809 (Australia)Stiffness, swelling, numbness, pain 16%-61% 21%-66%22%-54%
5. Paskett 200734622 (USA)Swelling20%36%44%48%54%
6. Hayes 201027285 (Australia)Tingling, weakness, pain, poor ROM, numbness, stiffness, swelling10%-29%10%-22%10%-19%  
7. Janz 2007421372 (USA)Breast, arm/shoulder pain46%-53%    

One challenge in drawing conclusions about the frequency of upper-body symptoms is that studies vary with regard to length of follow-up. There are 2 population-based studies that have assessed upper-body symptoms beyond 3 years. Results suggest similar prevalence at 4 to 5 years postsurgery (up to 56% of women report at least 1 symptom)24, 33 to that observed during 6 months to 3 years postsurgery. Also, the presence of multiple symptoms is more common than having 1 symptom alone. In a population-based, prospective cohort study of Australian women, the majority of those reporting moderate to extreme symptoms reported multiple symptoms between 6 and 18 months postsurgery (56%-68% across time points).27 In this issue of Cancer, it is noted that at 6 years postdiagnosis, >50% of breast cancer survivors from that same Australian cohort report 1 or more upper-body symptom (see Schmitz et al in this supplement).43 Taken together, these results indicate that upper-body morbidity is common after breast cancer and remains common well beyond the treatment period.

Lymphedema

Lymphedema is caused by a disruption of the lymphatic system that in the initial stages leads to the accumulation of fluid in the interstitial tissue space (that is, increases in extracellular fluid) and eventually clinically manifests as swelling of the arm, breast, shoulder, neck, or torso.44 Later stages of lymphedema are characterized by deposition of fibrotic and adipose tissue.45

It is well established that the chosen diagnostic method used to assess lymphedema influences the results found in observational studies.46-48 Bioimpedance spectroscopy assesses changes in extracellular fluid and has been shown to identify limb changes before clinical presentation of the condition and until the condition becomes nonpitting (fibrotic).49 Methods that assess limb size (such as water displacement, perometry, or circumferences), with or without conversion of the measure of size to limb volume, can detect nonpitting and pitting lymphedema of sufficient magnitude, but may be insensitive to early changes in extracellular fluid. Self-report methods (such as the Norman questionnaire,50 the Lymphedema Breast Cancer Questionnaire,51 the Lymphoedema Quality of Life Inventory,52 items from validated QOL-specific questionnaires [such as FACTB+453 and the European Organization for Research and Treatment of Cancer QLQ-C3054] or nonvalidated questions) take into account perceived sensory and size changes, as well as presence and intensity of related symptoms. However, as demonstrated earlier, the presence of symptoms is common in women after breast cancer, and this is irrespective of lymphedema status.27 A study that used multiple measures to assess lymphedema status in women 6 months after breast surgery found that 40% of those with objective lymphedema (defined by bioimpedance spectroscopy) did not self-report swelling, and 40% of those without objective lymphedema did.48 A USA-based study similarly found that breast cancer survivors met 4 different lymphedema criteria at various rates of occurrence (43%-94%), with 11% meeting all 4 criteria and 84% meeting at least 1 criterion.55 All clinical measures, when undertaken by trained personnel, and the validated self-report measures have proven repeatability. However, each method's accuracy in diagnosing cases (as well as avoiding misclassification of noncases) depends on which other diagnostic method it is being compared with.56 As yet, there is no agreement on which method, or combination of methods, reflects the most accurate diagnostic tool.

Given the variation in available diagnostic methods, which ultimately assess different attributes of lymphedema, it is not surprising that the extent of the public health burden posed by secondary lymphedema has long been clouded by wide variations in reported incidence. Reported rates in women after treatment for breast cancer have varied from 6% to 80%.57 Also contributing to the wide variation in incidence is timing of measurement (2 months to 20 years after breast cancer) and the type of cohort evaluated (studies may have included only those who underwent axillary dissection and/or radiation therapy).

In the past 5 years, 11 prospectively designed studies (graded as level II prognostic studies according to the National Health and Medical Research Council, Australia)58 have reported incidence estimates of secondary lymphedema after breast cancer (Table 2). These studies used objective diagnostic criteria and included samples generally representative of the larger breast cancer population. Median reported incidence in these 11 studies was 20% (range, 0%-94%). It therefore seems plausible to suggest that from 6 months postsurgery, approximately 1 in 5 patients treated for breast cancer will experience secondary lymphedema. The median rate appears to increase with longer follow-up, escalating from 11% up to 12 months to 36% beyond 12 months. Findings also suggest that 45% to 60% of patients with long-term secondary lymphedema present with the condition by 6 months postsurgery,46, 59 whereas 70% to 80% present by 12 months postsurgery.59, 60 Consequently, it seems clear that despite advances in breast cancer treatment over the past decade, lymphedema continues to be a common concern, with new cases presenting well beyond the active treatment period.

Table 2. Reported Incidence of Secondary Lymphedema (Objectively Measured) in Prospectively Designed Breast Cancer Cohort Studies Published Between 2007 and 2011
Country and StudySample SizeMethod of DiagnosisReported Incidence Postsurgery
6-Month PS12-Month PS18+-Month PS
  • Abbreviations: ALND, axillary lymph node dissection; BCT, breast-conserving treatment; BIS, bioimpedance spectroscopy; circ, circumferences; per, perometry; PS, postsurgery; RM, radical mastectomy; SD, standard deviation; SLNB, sentinel lymph node biopsy.

  • a

    Difference between limbs.

  • b

    Change from baseline.

  • c

    Range of occurrence rates of lymphedema measured at 18, 24, 30, 36, 48, or 60 months (using 3 definitions).

Australia     
 Hayes 200856211BIS, >3 SD than normative data, circ, >5 cm differencea11%8%-11%12%-15%
Belgium     
 Devoogdt 201115049circ, >10% differencea  18%
Canada     
 Helyer 2010151137per, >200 mL differencea  12%
 Thomas-MacLean 200838347circ, 3 definitions of differencea 9%-16% 
England     
 Bennett Britton 200715250circ, >10% differencea 11%28%
Korea     
 Yang 201041191circ, >1 cm differencea9%12.0% 
Norway     
 Nesvold 2008153263circ ≥2 cm changeb or ≥10% differencea  RM=20%, BCT=8%
Sweden     
 Celebioglu 200715460per, >10% differencea  SLNB=0%, ALND=20%
USA     
 Armer & Stewart 201055213circ, ≥2 cm change,b per ≥200 mL or ≥10% changeb11%-44%22%-66%29%-94%c
 McLaughlin 2008155936circ, >2 cm changeb  SLNB=5%, ALND=16%
 Wernicke 2011156223circ, 1 cm differencea  SLNB=5%, ALND=35%

Lymphedema is regarded as a persistent or chronic condition. However, results from 2 prospective studies, 1 using an objective measure60 of lymphedema status and the other a validated self-report measure,61 suggest this may not be the case for all women. The studies demonstrated that up to 60% of women with evidence of lymphedema had acute lymphedema (lasting no more than 5 months), dissipating with or without treatment (although commencement of, or adherence to, treatment was not formally assessed). Between 30% and 40% had chronic and/or progressive lymphedema, and between 15% and 22% had fluctuating lymphedema, which may have included intermittent periods without symptoms. Therefore, lymphedema seems transitory for some, with or without treatment, and long-term for others, with or without intermittent periods of relief. This variable nature of lymphedema may further contribute to the wide range of incidence reported throughout the literature. Importantly, however, those who present with mild lymphedema are at increased risk (up to 3× increased risk) of developing moderate to severe lymphedema.61, 62

Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

The extent of upper-body morbidity after treatment for breast cancer has been a major driving force in the quest for identifying less invasive treatment strategies that could reduce morbidity without adversely influencing survival.26 An established and growing literature base clearly demonstrates that upper-body morbidity is higher among those who undertake more invasive treatment options, such as axillary dissection versus sentinel node biopsy, mastectomy versus breast-conserving surgery, and/or radiation to the breast/chest wall and regional nodes versus radiation to the breast/chest wall only.31, 63-67

Injury to the intercostal brachial or thoracodorsal nerve may occur with axillary lymph node dissection and is a major cause of axillary paresthesia, muscular dysfunction (eg, dysfunction of the serratus anterior or latissimus dorsi), and pain.14, 68 Nerve injuries may resolve over several months without therapeutic intervention; however, muscle recruitment pattern, flow-on effect to surrounding musculature, and use of the arm may be permanently altered without intervention.69

Research on radiation-induced upper-body morbidity has uncovered a wide range of issues, including skin fragility,16, 17 fibrosis, and inflammatory changes to the soft tissue in the irradiated area,17, 70 as well as brachial plexopathies and other neuropathic impairments that may lead to sensory and motor changes.71-73 Radiation-induced soft tissue fibrosis is generally mild, and chronic radiation fibrosis is rare. Nonetheless, chronic fibrosis is significant and problematic, and unfortunately its development and effective management is not well understood. Clinically, it is noted that fibrosis contributes to diminished joint mobility and may foster short and potentially long-term shoulder, scapulae, and postural changes. Historically, because of poor shielding techniques and inadvertent exposure of the plexus to the radiation beam, radiation therapy has also contributed to severe brachial plexopathies and neuropathic impairments.71 However, modern techniques protect the brachial plexus and prevent inadvertent nerve damage. Brachial plexopathy is now considered rare, even in women for whom the supraclavicular and axillary regions are treated. Nonetheless, when it occurs, sensory and motor changes in the upper body occur, with severe cases experiencing paralysis. Results from 2 studies with >2 decades of follow-up72, 73 have shown that the rate of radiation-induced soft tissue damage and neuropathies was estimated to be 1% per year, netting a cumulative incidence of near 20% by 20 years post-therapy.72, 73 Although this incidence estimate may no longer be representative of women treated with radiation therapy for breast cancer today, it underscores the need for long-term follow-up.

The contribution of diagnostic factors (including tumor size, positive lymph node status, stage of cancer), physiological characteristics (such as lymphatic transport, vein wall movement, and venous anatomy and flow), and patient and behavioral characteristics (including body mass index, age, treatment on the dominant side, physical activity levels, and socioeconomic status) with respect to development of lymphedema have also been evaluated.57 To date, results derived from prospective cohort studies suggest that stage of disease, node status, and adjuvant therapy other than radiation therapy does not impact lymphedema risk.57 However, as adjuvant therapies continue to evolve, their relation with lymphedema risk will require continued exploration.

More work is also required to better understand the physiological changes associated with increased risk of lymphedema. Higher body mass index has long been considered a risk factor for lymphedema.59, 74-79 However, when findings from more recent studies are considered, the relation is less clear, with several prospective cohort studies demonstrating no relation between higher body mass index and lymphedema risk.9, 60, 80 Nonetheless, higher body mass index has never been associated with reduced risk, and the importance of maintaining healthy body weight in relation to other breast cancer outcomes is clear (see Demark-Wahnefried et al in this supplement).81 The relation between age and risk of lymphedema is mixed, with some studies showing no relation,9, 59, 80 whereas others show increased risk with increasing age.60, 82, 83 Race, upper-body function,60 and physical activity levels60, 84, 85 may also be associated with lymphedema risk; specifically, being African American,86 having lower than average upper-body function, and being sedentary have been associated with increased lymphedema risk.60 Finally, those with lymphedema are more likely to report multiple upper-body symptoms, and the presence of symptoms has been significantly associated with subsequent lymphedema development.27

Although several risk factors for the development of lymphedema have been identified, at present it is not possible to accurately predict who will and will not develop this condition.87 In a prospective, population-based study of 287 newly diagnosed breast cancer patients, 12 key treatment-related, personal, and behavioral characteristics were identified as important factors with respect to lymphedema risk. However, together they explained no greater than 35% of the variation between those who did and did not develop lymphedema.27

Methods to Detect Upper-Body Morbidity

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Self-report and objective methods available for detecting and monitoring lymphedema were reviewed in an earlier section (Incidence of Upper-Body Morbidity After Breast Cancer). When deciding which assessment method(s) are optimal, several factors must be considered, such as the sensitivity and specificity of the measure, whether the measure has been shown to detect subclinical lymphedema (before patients report symptoms), and whether the measure is affordable, transportable, practical for clinic use, noninvasive, and time efficient.88 Given that different methods assess different elements of lymphedema, the use of multiple assessment methods is ideal, particularly for tracking change over time.

Shoulder function can also be evaluated using any 1 or more of self-report or clinical methods. Validated questionnaires such as the BREAST-Q89 and the Disability of the Arm, Shoulder and Hand questionnaire90 provide comprehensive self-report assessment of upper-body morbidity, as well as the presence and severity of specific symptoms. Standardized procedures exist for the assessment of active and passive shoulder range of motion in all planes using goniometry,91 whereas strength and function can be assessed using isometric and isokinetic dynamometry and/or maximal or submaximal performance of set tasks/exercises using the repetition maximum method.92 However, upper-body assessment may also involve palpation of areas, particularly in the assessment of myofascial pain93 and tightness.31 Visual inspection of posture of the whole body, as well as the upper body in routine position, performance of spontaneous activities, and during planned tasks provides additional information regarding upper-body function.94 Finally, it is noted that a clinical assessment involves understanding existing function in addition to revealing specific impairments.94

Evidence-Based Prevention and Treatment Strategies

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Prevention strategies for minimizing upper-body morbidity have focused on the use of less invasive treatment methods when clinical presentation of the disease allows and the use of shoulder exercises after breast cancer surgery to optimize function. The evidence base for prevention and treatment of upper-body morbidity is presented below.

Upper-body symptoms and impairments

Studies that have assessed the effectiveness of postoperative physical therapy contend that physical therapy is beneficial for upper-body function and does not cause any adverse effects.95-99 These studies have been limited in sample size. In general, there is scant evidence base for the efficacy of rehabilitative (eg, physical therapy) or exercise interventions to prevent or treat upper-body symptoms or shoulder dysfunction in breast cancer survivors beyond studies specific to lymphedema. In the absence of a strong evidence base, the commonly used clinical approach to treating several upper-body symptoms and impairments is outlined below.

Standard physical therapy approaches to dealing with pain include gentle range of motion exercises, stretching, acupressure, and myofascial stretching, as well as dry needle techniques.93 Patient education to identify positions or activities that alleviate the symptoms is important for self-care management, and a gradual, progressive mobility program is encouraged. Clinically, pain management often requires an ongoing, multidisciplinary approach to monitor changes with treatment and assess response to medication. New onset pain or increasing pain may have additional etiologies, including tumor infiltration of the brachial plexus or tumor recurrence.100

Early assessment and intervention postsurgery, by way of education and shoulder exercises, are important to correct subtle treatment-related changes in scapulae position and stability that left untreated may lead to upper-body symptoms and impairments, and also to correct muscle recruitment imbalance.95, 101 Ongoing assessment and education is necessary to determine whether tissue changes that may occur during and beyond the adjuvant treatment period, such as shortening of the pectoralis major, perpetuate existing, or lead to the development of, upper-body morbidity.102 Range of motion exercises play a particularly important role during and after radiation treatment to enhance tissue extensibility and promote normal movement patterns101 and should be encouraged indefinitely to avoid tissue contracture and concomitant alterations to the joint mechanics of the shoulder. Furthermore, manual techniques such as myofascial release have also been considered useful in improving tissue extensibility and enhancing mobility.103

Lymphedema

In the prevention of lymphedema, 2 randomized, controlled trials, 1 evaluating the effectiveness of a “physiotherapy management care plan” (including education and progressive exercises)104 and the other evaluating a physical therapy program that included manual lymph drainage, massage of scar tissue, and progressive exercises,105 have demonstrated clinically relevant benefits. Both studies showed a higher proportion of women with lymphedema in the comparison group, compared with the physical therapy intervention group. The trial that included manual lymph drainage as part of the intervention demonstrated that the risk ratio for developing lymphedema in the intervention group was 0.25 (95% confidence interval, 1.10-0.79) compared with the control group. Results from another randomized, controlled trial suggest that delayed (7 days postoperative) versus early (within 48 hours postoperative) commencement of shoulder exercises was more favorable with respect to lymphedema development.106

Notably, however, the commonly available risk-reducing lymphedema guidelines are loosely based on what will minimize the production of lymph, which is directly proportional to blood flow, and what will minimize blockage to lymph transport.107 For example, heat, infections, and exercise may increase blood flow and therefore lymph production in the arm, whereas tight clothing may obstruct lymph flow.107 Unfortunately, the evidence to support or refute these guidelines is scarce. There is a clear need for well-designed, population-based, prospective studies to investigate the potential causal relation between participating in risky behaviors and subsequent lymphedema development. Until this occurs, it seems reasonable for prevention strategies to be discussed with women, especially in the context of encouraging healthy behaviors, such as participation in regular exercise and maintaining healthy body weight. In fact, results from a prospective, population-based cohort study as well as a randomized, controlled trial suggest that participating in regular exercise after breast cancer may prevent the development of lymphedema.60, 108

The goals of secondary lymphedema management include reduction of swelling, prevention of progression, alleviation of associated symptoms, prevention of infection, and improvement in function and QOL. Treatment options can be broadly categorized as conservative, surgical, pharmacologic, or alternative. The evidence behind lymphedema treatment options has previously been reviewed.57, 109, 110 Findings from these reviews, as well as results from treatment studies published in the past 3 years, are summarized below to provide an overview of the evidence for various lymphedema treatment options.

Treatment effects (limb volume reductions) for conservative treatment options are in the range of 8% to 66%, with several studies reporting continued reductions over 6 to 12 months follow-up. Volume reductions achieved by manual lymph drainage or pneumatic pumps tended to be higher when therapy was combined with other conservative treatment options, such as compression and massage. However, compression alone or in combination with other treatment led to volume reductions of 4% to 60% measured at 4 weeks to 6 months follow-up. When reported, response rates varied between 28% and 66%, and characteristics of those lost to follow-up were typically not reported. Lack of reference to clinically meaningful changes, questionable representativeness of the sample, potential bias caused by significant numbers lost to follow-up (likely more so for those not experiencing treatment effects), and lack of control group and/or adjustment for potential confounders severely influence the strength of these findings. Nonetheless, there is a growing body of low-level evidence in support of these therapies, which ultimately form the primary method currently used to treat lymphedema.111

Low-level laser therapy (light source treatment that generates light of a single wavelength, but does not emit heat, sound, or vibration) has been used as a form of lymphedema treatment since 1995 in some countries, but only received US Food and Drug Administration approval in 2007.112 Research in the area is limited and should be regarded as encouraging but preliminary. A randomized trial of low-level laser therapy (LTU-904 handheld laser; RianCorp, Richmond, Australia) in women with postmastectomy lymphedema reported a trend toward reductions in arm volumes over time after 2 cycles of treatment, but that despite these reductions, volumes at the 3-month follow-up were not statistically different from baseline values.113 Other studies have reported 16% to 79% volume reductions (using various handheld laser devices), but compare changes to another treatment group114 or lack a control group.112, 115, 116

There have been several investigations evaluating the role of exercise on lymphedema status, with various methodological qualities. Randomized, controlled trials have evaluated the role of combined exercise and relaxation therapy,117 aqua therapy,118 combined aerobic- and resistance-based exercise,119 and weight training.120, 121 Sample size within these studies ranged between 31 and 141, intervention duration ranged from 8 weeks to 12 months, and lymphedema status as well as other physical and psychosocial outcomes were typically assessed. All studies demonstrated that exercise did not exacerbate existing lymphedema and had positive effects on other outcomes influencing function and QOL. The largest of the trials, evaluating a 12-month weight-training intervention (n = 141), also demonstrated significant improvements in lymphedema-associated symptom severity, as well as reduced lymphedema exacerbations, compared with the control group.121 The results of these trials support the use of progressive exercise, with supervision at least in the earlier part of the intervention, in optimizing upper-body outcomes. Current lymphedema prevention guidelines have been labeled risk averse and may therefore encourage women to avoid use of their arms and bodies. Results from exercise intervention studies involving women with lymphedema highlight the need for encouragement rather than avoidance of participation in physical activity after breast cancer.122

The association between body weight and lymphedema risk has led to 2 studies investigating the potential for weight-reduction strategies to reduce lymphedema.123, 124 Although results suggest that weight-reducing strategies may be useful in the management of lymphedema, further studies utilizing larger sample sizes and lymphedema assessment methods that are not sensitive to weight changes are warranted (eg, bioelectrical impedance spectroscopy).

The use of medications to manage secondary lymphedema is of continued interest, with emphasis to date being placed on benzopyrones and selenium compounds. Systematic reviews of the literature evaluating the use of these compounds in lymphedema management report that there is no evidence in support of their use.125, 126 More recently, a randomized, controlled study of 12 months treatment with pentoxifylline (which is used to improve blood flow through peripheral blood vessels) and vitamin E for the prevention of radiation-induced side effects in breast cancer patients (n = 83) showed increases in arm volume in the control group but no change in the intervention group.127

Surgery for lymphedema includes debulking procedures to remove excess skin and subcutaneous tissue (eg, liposuction) or the creation of new pathways for draining lymph (eg, microsurgery, lymphatic-venous anastomosis). Surgery is typically only recommended when conservative treatment options have failed to be effective, and lymphedema is chronic and pitting. Although limited by study design (comparative studies without concurrent controls or case series) and small sample size, excellent results from studies evaluating liposuction128-130 and lymphatic vessel-isolated vein anastomosis131, 132 have been reported, with complete resolution of excess limb volume, in addition to improvements in function and QOL, being reported in several liposuction studies.128-130 The potential for scarring and other complications, as well as the need for continued use of compression garments after surgery, restricts the use of this treatment to a specific subset of women with relatively severe lymphedema who experience no response to conservative treatment.

There is significant room for improvement in studies evaluating treatment for lymphedema. Weak designs continue to influence the strength of the findings reported, and there is high potential for over-reporting of treatment effects. Despite the need for more research into effective lymphedema treatment strategies, several treatment guidelines have been developed using the available evidence (Australia: National Breast and Ovarian Cancer Centre133; Canada: Health Canadal134; Europe: European Society for Breast Cancer Specialists135; Sweden: Swedish Cancer Society136; United Kingdom: National Institute for Health and Clinical Excellence, Clinical Resources Efficiency Support Team137; USA: National Lymphedema Network,138 Agency for Healthcare Research and Quality,139 and Oncology Nursing Society140).

Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Prospective surveillance may play an important role in the early detection and management of upper-body morbidity. Within the broader breast cancer setting, impairments detected within the hospital setting are more likely to receive intervention, and this is particularly the case for low socioeconomic and minority status groups.141, 142 This may be as a consequence of increased scrutiny in the inpatient setting, the presence of critical pathways, and/or the absence of specific access barriers.

More specific to upper-body morbidity, however, results from a prospective, cohort study provide preliminary findings that support the integration of formal regular surveillance.143 In this study, lymphedema was identified in 43 of 196 women prospectively followed. When an increase in limb volume of >3% compared with preoperative volume (as assessed via perometry) was observed, compression garments were prescribed for 4 weeks. Limb volumes were significantly reduced after the compression garment period. Notably this was a cohort study and not a randomized, controlled treatment trial, limiting the strength of these findings. Nonetheless, even if the 3% limb volume change represented postsurgical swelling, which may spontaneously resolve, other research has reported higher risk for lymphedema at 6 to 9 months after surgery after postsurgical swelling.144 Furthermore, others have also demonstrated that those with mild lymphedema are at greater risk of developing chronic and more severe lymphedema.61 Importantly, this prospective surveillance cohort study demonstrated that regular assessment of upper-body morbidity (including preoperative measures) in a busy breast cancer clinic is possible, and that women were accepting of wearing compression garments for a 4-week period (although compliance with garment wear was not tracked). This garment intervention is in contrast to many lymphedema treatment options that are considered costly with respect to time, finances, and lifestyle.57 These findings are supported by another prospective breast cancer cohort study, which spanned a 10-year period (n = 292).145 Results from this study also demonstrated that the integration of regular surveillance is feasible and beneficial. Furthermore, early diagnosis and treatment translated to more manageable lymphedema; 80% of those diagnosed with lymphedema throughout the follow-up period did not exceed 20% limb ratio volumes.

The personal costs associated with lymphedema are well known and documented, but data have only recently become available to demonstrate the potential overall financial costs. Women with lymphedema after breast cancer have between $14,887 and $23,167 more medical costs when compared with women without lymphedema.146 Women with lymphedema also have more productive days lost than those without (73 vs 56 days). So although there is a clear desire to minimize overdiagnosis of lymphedema, this must be balanced by what may be gained with early diagnosis and intervention.

The evidence presented throughout this paper provides support for the integration of regular surveillance of upper-body morbidity within standard breast cancer care, as is recommended by the prospective model published in this supplement (see Stout et al in this supplement).147 Preoperative assessment of upper-body morbidity is ideal, particularly for bilateral breast cancer cases; however, preoperative assessment is not true baseline, with the contribution of the cancer to upper-body morbidity currently unknown. Furthermore, regular postoperative surveillance can still be successful in the absence of preoperative measures. For unilateral breast cancer, presence and severity of upper-body symptoms, impairments, and lymphedema can be compared with the contralateral limb, and for some lymphedema measures, such as bioimpedance spectroscopy, comparisons can be made with the lower limb in the absence of an unaffected upper limb.148 Long-term follow-up after breast cancer has merit because of the observations that physical impairments may persist for years after treatment (see Schmitz et al in this supplement)43 and that some types of upper-body morbidities (eg, radiation damage) may persist for decades after treatment.71, 72

Comprehensive assessment of upper-body morbidity using clinical and self-report methods is ideal, although it may be impractical to administer in a busy clinic setting. A possible solution may be to ensure comprehensive assessment occurs in the first instance (preoperative and/or first postoperative assessment), with subsequent reliance on 1 or select method(s) for follow-up measurements, with adverse changes in self-report symptoms or the clinical measure dictating a subsequent more comprehensive assessment. Regularity of the measurement may be variable within treating centers and scheduled among normal postoperative adjuvant treatment or postadjuvant treatment visits. Monthly to once every 3 months seems a reasonable surveillance interval, through to 12 months postsurgery, with less regular surveillance occurring beyond that period. Given that lymphedema may be transient, fluctuating, or chronic, consideration may be given to increasing regularity of surveillance when clinical evidence of the condition presents or patients self-report change in symptoms, and initiation of treatment only after a predefined threshold (volume or time) is met. Also, diagnosis of lymphedema within the first 3 months after surgery or radiation is cautioned, as there is the risk of misclassifying normal post-treatment swelling. Surveillance should be supplemented with patient education on early signs and symptoms of upper-body morbidity, in particular progression of severity of concerns.149

Summary

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Upper-body morbidity is common after breast cancer, and although more extensive treatment has been consistently linked with higher incidence of morbidity, morbidity remains common despite the introduction of less invasive treatment options. Upper-body symptoms, impairments, and lymphedema typically present within the first 12 months after breast surgery (although cases can present years later), and as such, integration of regular surveillance into standard breast cancer care is considered appropriate and has been shown to be feasible. Participation in regular and progressive physical activity after a breast cancer diagnosis may optimize function and QOL, as well as minimize upper-body morbidity. Upper-body morbidity seems amenable to physical therapies, with early diagnosis likely facilitating more effective treatment, as well as prevention of progression.

FUNDING SUPPORT

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES

Support for this meeting and supplement was provided by the American Cancer Society, through the Longaberger Company®, a direct selling company offering home products including handcrafted baskets made in Ohio, and the Longaberger Horizon of Hope® Campaign, which provided a grant to the American Cancer Society for breast cancer research and education. S.C.H.'s fellowship position is supported by the National Breast Cancer Foundation, Australia.

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

REFERENCES

  1. Top of page
  2. Abstract
  3. Overview of the Epidemiology of Upper-Body Morbidity
  4. Incidence of Upper-Body Morbidity After Breast Cancer
  5. Identifying Known Risk Factors for the Development or Exacerbation of Upper-Body Morbidity
  6. Methods to Detect Upper-Body Morbidity
  7. Evidence-Based Prevention and Treatment Strategies
  8. Overview of the Potential Role That Prospective Surveillance Would Play in Early Identification and Treatment, and Whether There Is a Need to Establish Baseline Measures
  9. Summary
  10. Acknowledgements
  11. FUNDING SUPPORT
  12. REFERENCES
  • 1
    Engel J, Kerr J, Schlesigner-Raab A, Eckel R, Sauer H, Holzel D. Predictors of quality of life of breast cancer patients. Acta Oncol. 2003; 42: 710-718.
  • 2
    Karki A, Simonen R, Malkia E, Selfe J. Impairments, activity limitations and participation restrictions 6 and 12 months after breast cancer operation. J Rehabil Med. 2005; 37: 180-188.
  • 3
    Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002; 20: 4242-4248.
  • 4
    Hayes S, Rye S, Battistutta D, DiSipio T, Newman B. Upper-body morbidity following breast cancer treatment is common, may persist longer-term and adversely influences quality of life. Health Qual Life Outcomes. 2010; 8: 92.
  • 5
    Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998; 83: 2776-2781.
  • 6
    Carter BJ. Women's experiences of lymphoedema. Oncol Nurs Forum. 1997; 24: 875-882.
  • 7
    Johansson K, Holmstrom H, Nilsson I, Ingvar C, Albertsson M, Ekdahl C. Breast cancer patients' experiences of lymphodema. Scand J Caring Sci. 2003; 17: 35-42.
  • 8
    Bafford A, Gadd M, Gu X, Lipsitz S, Golshan M. Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma. Am J Surg. 2010; 200: 374-377.
  • 9
    Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007; 25: 3657-3663.
  • 10
    Teh B, Woo S, Butler B. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist. 1999; 4: 433-442.
  • 11
    Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008; 26: 2085-2092.
  • 12
    Gomide LB, Matheus JPC, Candido dos Reis FJ. Morbidity after breast cancer treatment and physiotherapeutic performance. Int J Clin Pract. 2007; 61: 972-982.
  • 13
    Rietman JS, Kijkstra PU, Hoekstra HJ, et al. Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: a systematic review. Eur J Surg Oncol. 2003; 29: 229-238.
  • 14
    Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009; 302: 1985-1992.
  • 15
    Torres Lacomba M, Mayoral del Moral O, Coperias Zazo JL, Gerwin RD, Goni AZ. Incidence of myofascial pain syndrome in breast cancer surgery: a prospective study. Clin J Pain. 2010; 26: 320-325.
  • 16
    Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 1995; 31: 1171-1185.
  • 17
    Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995; 31: 1141-1164.
  • 18
    Lopez E, Guerrero R, Nunez MI, et al. Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Res. 2005; 7: R690-R698.
  • 19
    Pugliese GN, Green RF, Antonacci A. Radiation-induced long thoracic nerve palsy. Cancer. 1987; 60: 1247-1248.
  • 20
    Gerber L, Lampert M, Wood C, et al. Comparison of pain, motion, and edema after modified radical mastectomy vs. local excision with axillary dissection and radiation. Breast Cancer Res Treat. 1992; 21: 139-145.
  • 21
    Wallgren A. Late effects of radiotherapy in the treatment of breast cancer. Acta Oncol. 1992; 31: 237-242.
  • 22
    Albert U, Koller M, Kopp I, Lorenz W, Schulz K, Wagner U. Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study. Breast Cancer Res Treat. 2006; 100: 285-292.
  • 23
    Arndt V, Stegmaier C, Ziegler H, Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer. 2006; 107: 2496-2503.
  • 24
    Engel J, Kerr J, Schlesinger-Rabb A, Sauer H, Holzel D. Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat. 2003; 79: 47-57.
  • 25
    Ernst MF, Voogd AC, Balder W, Klinkenbijl JHG, Roukema JA. Early and late morbidity associated with axillary levels I-III dissection in breast cancer. J Surg Oncol. 2002; 79: 151-155.
  • 26
    Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomised controlled surgical trial. Ann Surg Oncol. 2009; 16: 266-275.
  • 27
    Hayes SC, Rye S, Battistutta D, Newman B. Prevalence of upper-body symptoms following breast cancer and its relationship with upper-body function and lymphedema. Lymphology. 2010; 43: 178-187.
  • 28
    Husted Madsen A, Haugaard K, Soerensen J, et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast. 2008; 17: 138-147.
  • 29
    Janz N, Mujahad M, Lantz P, et al. Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer. Qual Life Res. 2005; 14: 1467-1479.
  • 30
    Lauridsen MC, Torsleff KR, Husted H, Erichsen C. Physiotherapy treatment of late symptoms following surgical treatment of breast cancer. Breast. 2000; 9: 45-51.
  • 31
    Leidenius M, Leppanen E, Krogerus L, Von Smitten K. Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg. 2003; 185: 127-130.
  • 32
    Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98: 599-609.
  • 33
    McCredie MRE, Dite GS, Porter L, et al. Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. Breast. 2001; 10: 515-522.
  • 34
    Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007; 16: 775-782.
  • 35
    Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005; 23: 4312-4321.
  • 36
    Rietman JS, Dijkstra PU, Geertzen JHB, et al. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma. Cancer. 2003; 98: 690-696.
  • 37
    Rietman JS, Geertzen JHB, Hoekstra HJ, et al. Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Euro J Surg Oncol. 2006; 32: 148-152.
  • 38
    Thomas-MacLean RL, Hack T, Kwan W, Towers A, Miedema B, Tilley A. Arm morbidity and disability after breast cancer: new directions for Care. Oncol Nurs Forum. 2008; 35: 65-71.
  • 39
    Ronka R, von Smitten K, Tasmuth T, Leidenius M. One-year morbidity after sentinel node biopsy and breast surgery. Breast. 2005; 14: 28-36.
  • 40
    So WK, Marsh G, Ling WM, et al. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum. 2009; 36: E205-E214.
  • 41
    Yang EJ, Park WB, Seo KS, Kim SW, Heo CY, Lim JY. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. J Surg Oncol. 2010; 101: 84-91.
  • 42
    Janz NK, Mujahid M, Chung LK, et al. Symptom experience and quality of life of women following breast cancer treatment. J Womens Health. 2007; 16: 1348-1361.
  • 43
    Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. Cancer. 2012; 118( suppl 8): 2217-2225.
  • 44
    Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thiadens SR, Taylor ME. The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol. 2003; 13: 214-225.
  • 45
    Casley-Smith JR. Alterations of untreated lymphedema and its grades over time. Lymphology. 1995; 28: 174-185.
  • 46
    Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005; 3: 208-217.
  • 47
    Czerniec SA, Ward LC, Refshauge KM, et al. Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Invest. 2010; 28: 54-62.
  • 48
    Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat. 2005; 89: 221-226.
  • 49
    Cornish BH, Thomas BJ, Ward LC, Hirst C, Bunce IH. A new technique for the quantification of peripheral edema with application in both unilateral and bilateral cases. Angiology. 2002; 53: 41-47.
  • 50
    Norman SA, Miller LT, Erikson HB, Norman MF, McCorkle R. Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer. Phys Ther. 2001; 81: 1192-1205.
  • 51
    Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003; 52: 370-379.
  • 52
    Klernas P, Kristjanson LJ, Johansson K. Assessment of quality of life in lymphedema patients: validity and reliability of the Swedish version of the Lymphedema Quality of Life Inventory (LQOLI). Lymphology. 2010; 43: 135-145.
  • 53
    Brady M, Cella D, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol. 1997; 15: 974-986.
  • 54
    Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996; 14: 2756-2768.
  • 55
    Armer J, Stewart B. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010; 43: 118-127.
  • 56
    Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphoedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence and identifiable risk factors. Lymphology. 2008; 41: 18-28.
  • 57
    Hayes SC. Review of Research Evidence on Secondary Lymphoedema: Incidence, Prevention, Risk Factors and Treatment. National Breast and Ovarian Cancer Centre; 2008.
  • 58
    National Health and Medical Research Council. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines, pilot program 2005-2007, Canberra, Australia.
  • 59
    Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. Q J Med. 2005; 98: 343-348.
  • 60
    Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphoedema following breast cancer: incidence, risk factors and effect on upper body function. J Clin Oncol. 2008; 26: 3536-3542.
  • 61
    Norman S, Localio A, Potashnik S, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009; 27: 390-397.
  • 62
    Bar Ad V, Cheville A, Solin LJ, Dutta P, Both S, Harris EE. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010; 76: 85-90.
  • 63
    Gosselink R, Rouffaer L, Vanhelden P, Piot W, Troosters T, Christiaens M. Recovery of upper limb function after axillary dissection. J Surg Oncol. 2003; 83: 204-211.
  • 64
    Haid A, Koberle-Wuhrer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillar dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat. 2002; 73: 31-36.
  • 65
    Peintinger F, Reitsamer R, Stranzi H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003; 89: 648-652.
  • 66
    Rietman JS, Kijkstra PU, Geertzen JHB, et al. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol. 2004; 11: 1018-1024.
  • 67
    Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000; 88: 608-614.
  • 68
    Mostafa A, Mokbel K, Engledow A, et al. Is dissection of the internerve tissue during axillary lymphadenectomy for breast cancer necessary? Eur J Surg Oncol. 2000; 26: 153-154.
  • 69
    Duncan MA, Lotze MT, Gerber LH, Rosenberg SA. Incidence, recovery, and management of serratus anterior muscle palsy after axillary node dissection. Phys Ther. 1983; 63: 1243-1247.
  • 70
    Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol. 1995; 35: 83-90.
  • 71
    Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys. 2000; 48: 745-750.
  • 72
    Bajrovic A, Rades D, Fehlauer F, et al. Is there a life-long risk of brachial plexopathy after radiotherapy of supraclavicular lymph nodes in breast cancer patients? Radiother Oncol. 2004; 71: 297-301.
  • 73
    Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol. 1990; 18: 213-220.
  • 74
    Edwards TL. Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. Aust N Z J Surg. 2000; 70: 412-418.
  • 75
    Petrek JA. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001; 92: 1368-1377.
  • 76
    Segerstrom K, Bjerle P, Graffman S, Nystrom A. Factors that influence the incidence of brachial oedema after treatment of breast cancer. Scand J Plast Reconst Surg Hand Surg. 1992; 26: 223-227.
  • 77
    Kopanski Z, Wojewoda T, Wojewoda A, Schlegel-Zawadzka M, Wozniacka R, Suder A. Influence of some anthropometric parameters on the risk of development of distal complications after mastectomy carried out because of breast carcinoma. Am J Hum Biol. 2003; 15: 433-439.
  • 78
    Ozaslan C, Kuru B. Lymphedema after treatment of breast cancer. Am J Surg. 2004; 187: 69-72.
  • 79
    van der Veen P, De Voogdt N, Lievens P, Duquet W, Lamote J, Sacre R. Lymphoedema development following breast cancer surgery with full axillary section. Lymphology. 2004; 37: 206-208.
  • 80
    Francis WP, Abghari P, Du W, Rymal C, Suna M, Kosir MA. Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg. 2006; 192: 636-639.
  • 81
    Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012; 118(suppl 8): 2277-2287.
  • 82
    Graham P, Jagavkar R, Browne L, Millar E. Supraclavicular radiotherapy must be limited laterally by the coracoid to avoid significant adjuvant breast nodal radiotherapy lymphoedema risk. Australas Radiol. 2006; 50: 578-582.
  • 83
    Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006; 13: 491-500.
  • 84
    Arrault M, Vignes S. Risk factors for developing upper limb lymphedema after breast cancer treatment [in French]. Bull Cancer. 2006; 93: 1001-1006.
  • 85
    Johansson K, Ohlsson K, Ingvar C, Albertsson M, Ekdahl C. Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology. 2002; 35: 59-71.
  • 86
    Kwan ML, Darbinian J, Schmitz KH, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010; 145: 1055-1063.
  • 87
    Rockson SG. Precipitating factors in lymphoedema: myths and realities. Cancer. 1998; 83: 2814-2816.
  • 88
    Piller N, Keeley V, Ryan T, Hayes S, Ridner S. Early detection—a strategy to reduce risk and severity. J Lymphoedema. 2009; 4: 89-95.
  • 89
    Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009; 124: 345-353.
  • 90
    Solway S, Beaton D, McConnell S, Bombardier C. The DASH Outcome Measure User's Manual. 2nd ed. Toronto, Canada: Institute for Work and Health; 2002.
  • 91
    Norkin C, White D. Measurement of Joint Motion: A Guide to Goniometry. Philadelphia, PA: FA Davis Company; 1995.
  • 92
    Hall C, Brody L. Therapeutic Exercise: Moving Towards Function. In: Hall C, Brody L, eds. Baltimore, MD: Lippincott, Williams, and Wilkins; 2005: 57-86.
  • 93
    Simons D, Travell J, Simons LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol 1. Upper Half of the Body. 2nd ed. Baltimore, MD: Lippincott, Williams, and Wilkins; 1998.
  • 94
    Magarey ME, Jones MA. Dynamic evaluation and early management of altered motor control around the shoulder complex. Man Ther. 2003; 8: 195-206.
  • 95
    Cinar N, Seckin U, Keskin D, Bodur H, Bozkurt B, Cengiz O. The effectiveness of early rehabilitation in patients with modified radical mastectomy. Cancer Nurs. 2008; 31: 160-165.
  • 96
    Na YM, Lee JS, Park JS, Kang SW, Lee HD, Koo JY. Early rehabilitation program in postmastectomy patients: a prospective clinical trial. Yonsei Med J. 1999; 40: 1-8.
  • 97
    Todd J, Topping A. A survey of written information on the use of post-operative exercises after breast cancer surgery. Physiotherapy. 2005; 91: 87-93.
  • 98
    Shamley DR, Barker K, Simonite V, Beardshaw A. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005; 90: 263-271.
  • 99
    Beurskens CHG, van Uden CJT, Strobbe LJA, Oostendorp RAB, Wobbes T. The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer, a randomised controlled study. BMC Cancer. 2007; 7: 166.
  • 100
    Loftus LS, Laronga C. Evaluating patients with chronic pain after breast cancer surgery: the search for relief. JAMA. 2009; 302: 2034-2035.
  • 101
    Lee SA, Kang JY, Kim YD, et al. Effects of a scapula-oriented shoulder exercise programme on upper limb dysfunction in breast cancer survivors: a randomized controlled pilot trial. Clin Rehabil. 2010; 24: 600-613.
  • 102
    Stegink-Jansen CW, Buford WLJr, Patterson RM, Gould LJ. Computer simulation of pectoralis major muscle strain to guide exercise protocols for patients after breast cancer surgery. J Orthop Sports Phys Ther. 2011; 41: 417-426.
  • 103
    Crawford JS, Simpson J, Crawford P. Myofascial release provides symptomatic relief from chest wall tenderness occasionally seen following lumpectomy and radiation in breast cancer patients. Int J Radiat Oncol Biol Phys. 1996; 34: 1188-1189.
  • 104
    Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM. Physiotherapy after breast cancer surgery: results of a randomised controlled study to minimise lymphoedema. Breast Cancer Res Treat. 2002; 75: 51-64.
  • 105
    Torres Lacomba M, Jose Yuste Sanchez M, Zapico Goni A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010; 340: b5396.
  • 106
    Todd J, Scally A, Dodwell D, Horgaan K, Topping A. A randomised controlled trial of two programmes of shoulder exercise following axillary lymph node dissection for invasive breast cancer. Physiotherapy. 2008; 94: 265-273.
  • 107
    Petrek JA, Pressman P, Smith R. Lymphoedema: current issues in research and management. CA Cancer J Clin. 2000; 50: 292-307.
  • 108
    Schmitz K, Ahmed R, Troxel A, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 2010; 304: 2699-2705.
  • 109
    Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs [review]. Cochrane Database Syst Rev. 2004;( 4): CD003141.
  • 110
    Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. Ann Oncol. 2007; 18: 639-646.
  • 111
    Langbecker D, Hayes SC, Newman B, Janda M. Treatment for upper-limb and lower-limb lymphedema by professionals specialising in lymphedema care. Eur J Cancer Care. 2008; 17: 557-564.
  • 112
    Dirican A, Andacoglu O, Johnson R, McGuire K, Mager L, Soran A. The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema. Support Care Cancer. 2011; 19: 685-690.
  • 113
    Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy. Cancer. 2003; 98: 1114-1122.
  • 114
    Lau RW, Cheing GL. Managing postmastectomy lymphedema with low-level laser therapy. Photomed Laser Surg. 2009; 27: 763-769.
  • 115
    Kozanoglu E, Basaran S, Paydas S, Sarpel T. Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial. Clin Rehabil. 2009; 23: 117-124.
  • 116
    Piller NB, Thelander A. A cost effective treatment to reduce post mastectomy lymphoedema. Lymphology. 1996; 31: 74-86.
  • 117
    McClure MK, McClure RJ, Day R, Brufsky AM. Randomized controlled trial of the Breast Cancer Recovery Program for women with breast cancer-related lymphedema. Am J Occup Ther. 2010; 64: 59-72.
  • 118
    Tidhar D, Katz-Leurer M. Aqua lymphatic therapy in women who suffer from breast cancer treatment-related lymphedema: a randomized controlled study. Support Care Cancer. 2010; 18: 383-392.
  • 119
    Hayes SC, Reul-Hirche H, Turner J. Exercise and secondary lymphedema: safety, potential benefits, and research issues. Med Sci Sports Exerc. 2009; 41: 483-489.
  • 120
    Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol. 2006; 24: 2765-2772.
  • 121
    Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphoedema. New Engl J Med. 2009; 361: 661-673.
  • 122
    Schmitz KH. Balancing lymphedema risk: exercise versus deconditioning for breast cancer survivors. Exerc Sport Sci Rev. 2010; 38: 17-24.
  • 123
    Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer. 2007; 109: 1949-1956.
  • 124
    Shaw C, Mortimer P, Judd PA. A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema. Cancer. 2007; 110: 1868-1874.
  • 125
    Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2003;( 4): CD003140.
  • 126
    Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006;( 3): CD005037.
  • 127
    Magnusson M, Hoglund P, Johansson K, et al. Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). Eur J Cancer. 2009; 45: 2488-2495.
  • 128
    Bagheri S, Ohlin K, Olsson G, Brorson H. Tissue tonometry before and after liposuction of arm lymphedema following breast cancer. Lymphat Res Biol. 2005; 3: 66-80.
  • 129
    Brorson H, Ohlin K, Olsson G, Langstrom G, Wiklund I, Svensson H. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology. 2006; 39: 8-25.
  • 130
    Brorson H, Ohlin K, Olsson G, Nilsson M. Adipose tissue dominates chronic arm lymphedema following breast cancer: an analysis using volume rendered CT images. Lymphat Res Biol. 2006; 4: 199-210.
  • 131
    Matsubara S, Sakuda H, Nakaema M, Kuniyoshi Y. Long-term results of microscopic lymphatic vessel-isolated vein anastomosis for secondary lymphedema of the lower extremities. Surg Today. 2006; 36: 859-864.
  • 132
    Damstra RJ, Voesten HG, van Schelven WD, van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat. 2009; 113: 199-206.
  • 133
    National Breast and Ovarian Cancer Centre. Resource: Lymphoedema, What You Need to Know. Available at: http://canceraustralia.nbocc.org.au/view-document-details/lnkc-lymphoedema-what-you-need-to-know Accessed August 30, 2011.
  • 134
    Harris SR, Hugi MR, Olivotto IA, Levine M, for the Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ. 2001; 164: 191-199.
  • 135
    European Society for Breast Cancer Specialists. Available at: http://www.eusoma.org/Index.aspx Accessed August 30, 2011.
  • 136
    Swedish Cancer Society. Available at: http://www.cancerfonden.se/sv/Information-in-English/ Accessed August 30, 2011.
  • 137
    National Institute for Health and Clinical Excellence. Breast Cancer: Completed Guidelines. Available at: http://guidance.nice.org.uk/Topic/Cancer/Breast Accessed August 30, 2011.
  • 138
    National Lymphedema Network. Lymphedema Position Papers. Available at: http://www.lymphnet.org/lymphedemaFAQs/positionPapers.htm Accessed August 30, 2011.
  • 139
    Agency for Healthcare Research and Quality. Technology Assessment: Diagnosis and Treatment of Secondary Lymphedema. Available at: http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=66&bc=BAAgAAAAAA AA& Accessed August 30, 2011.
  • 140
    Oncology Nursing Society. Lymphedema. Available at: http://www. ons.org/Research/PEP/Lymphedema Accessed August 30, 2011.
  • 141
    Cheville AL, Beck LA, Petersen TL, Marks RS, Gamble GL. The detection and treatment of cancer-related functional problems in an outpatient setting. Support Care Cancer. 2009; 17: 61-67.
  • 142
    Cheville AL, Troxel AB, Basford JR, Kornblith AB. Prevalence and treatment patterns of physical impairments in patients with metastatic breast cancer. J Clin Oncol. 2008; 26: 2621-2629.
  • 143
    Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008; 112: 2809-2819.
  • 144
    Mahamaneerat WK, Shyu C-R, Stewart BR, Armer JM. Breast cancer treatment, BMI, post-op swelling/lymphoedema. J Lymphedema. 2008; 3: 38-44.
  • 145
    Johansson K, Branje E. Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis. Acta Oncol. 2010; 49: 166-173.
  • 146
    Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009; 27: 2007-2014.
  • 147
    Stout NL, Andrews K, Binkley JM, Schmitz KH, Smith RA. Prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012; 118(suppl 8): 2191-2200.
  • 148
    Ward L, Winall A, Isenring E, et al. Assessment of bilateral limb lymphedema by bioelectrical impedance spectroscopy. Int J Gynecol Cancer. 2011; 21: 409-418.
  • 149
    Fu MR, Chen CM, Haber J, Guth AA, Axelrod D. The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors. Ann Surg Oncol. 2010; 17: 1847-1853.
  • 150
    Devoogdt N, Kampen M, Christiaens M, et al. Short- and long-term recovery of upper limb function after axillary lymph node dissection. Eur J Cancer Care. 2011; 20: 77-86.
  • 151
    Helyer L, Varnic M, Le L, Leong W, McCready D. Obesity is a risk factor for development postoperative lymphedema in breast cancer patients. Breast J. 2010; 16: 48-54.
  • 152
    Bennett Britton TM, Buczacki SJA, Turner CL, Vowler SL, Pain SJ, Purushotham AD. Venous changes and lymphoedema 4 years after axillary surgery for breast cancer. Br J Surg. 2007; 94: 833-834.
  • 153
    Nesvold I, Dahl A, Lokkevik E, Marit Mengshoel A, Fossa S. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol. 2008; 47: 835-842.
  • 154
    Celebioglu F, Perbeck L, Frisell J, Grondal E, Svensson L, Danielsson R. Lymph drainage studied by lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph node dissection following conservative breast cancer surgery. Acta Radiol. 2007; 48: 488-495.
  • 155
    McLaughlin S, Wright M, Morris K, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008; 26: 5213-5219.
  • 156
    Wernicke A, Goodman R, Turner B, et al. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res Treat. 2011; 125: 893-902.